VictoryShares US Discovery Enhanced Volatility Wtd ETF CSF
51.03 USD +0.14 (+0.28%)
At closeApr 23, 2025, 4:00 PM EDT
51.00 Day range 51.39
46.65 52-week range 60.63
- YTD
- -7.02%
- 1 year
- +3.34%
News
gurufocus.com TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company's Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an inves
gurufocus.com Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease [url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial result
marketbeat.com Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study Arrowhead Pharmaceuticals NASDAQ: ARWR presented interim Phase I/II data for ARO-MAPT, an investigational small interfering RNA therapy designed to reduce tau protein expression in the central…
globenewswire.com Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests Cerenome secures Florida Blue agreement for CNSide tumor cell and molecular tests, expanding contracted payer access to approximately 164M covered lives.
globenewswire.com Cerenome Launches CNSide® CSF Molecular Profile Tests HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of…
gurufocus.com New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple I
gurufocus.com Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t [url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
businesswire.com Chime Scholars Foundation Announces 2026–2027 Cohort SAN FRANCISCO--(BUSINESS WIRE)--Chime® (Nasdaq: CHYM), America's #1 choice for banking1, today announced its 2026–2027 Chime Scholars Foundation® (CSF) cohort, awarding $3 million in scholarships to…
globenewswire.com Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF…
gurufocus.com Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease [url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranerse
proactiveinvestors.com Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from the College of American Pathologists, a widely recognized standard in laboratory quality, sending…
globenewswire.com Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption New dedicated billing code facilitates payer reimbursement, supports clinician adoptions, and enables national utilization tracking New dedicated billing code facilitates payer reimbursement,…
globenewswire.com Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new payer…
globenewswire.com Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals…
globenewswire.com Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3…
globenewswire.com Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA) Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotype BLA resubmitted to U.S. FDA in January 2026; Company expects up to six-month review period per FDA…
zacks.com Digital Realty Taps Malaysia for Expansion Through CSF Advisers Buyout DLR's Malaysia entry strengthens its Southeast Asia footprint, adding scalable capacity, dense connectivity and a new hub to support regional digital growth.
businesswire.com UL Solutions Warns of Mislabeled Child Life Jackets NORTHBROOK, Ill.--(BUSINESS WIRE)--UL Solutions, a global leader in applied safety science, today issued a warning that a limited run of Kent Watersports CSF-2 child life jackets was mislabeled by…
globenewswire.com New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF TOKYO and CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,…
globenewswire.com Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference CNSide can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations CNSide may catalyze